PSP occurs when excess Tau protein damages the brain cells and is a supranuclear disease, since it damages the nuclei that control eye movements. The common symptoms of the disease are loss of balance, fast walking, bumping into objects or people, falling, dementia, slurring of speech, difficulty in swallowing, poor working of eyelids, sleep disruption, urinary incontinence, and constipation. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scan are used as testing procedures for PSP diagnosis. AbbVie Inc. is in the process of developing ABBV-8E12 for the treatment of the disease. Many companies are more focused on developing their drug candidates as small molecule with the oral route of administration in the PSP therapeutics pipeline. No medication is effective in halting the progression of the disease however, several medications, including dopamine agonists, tricyclic antidepressants, and methysergide, may provide modest symptomatic improvement.
PROGRESSIVE SUPRANUCLEAR PALSY THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
As of November 2017, the PSP therapeutics pipeline comprises of approximately 14 drug candidates in different stages of development.
Some of the key players developing drugs for the treatment of PSP include AbbVie Inc., Biogen Inc., Asceneuron SA, Intellect Neurosciences, Inc. and others.
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles